6/28/23, 12:10 AM CLARITY Pathway Feedback Search Clinical Topics Home Studies CLARITY CLARITY Disease COVID 19 infection Trial question What is the role of ARBs in patients with COVID-19 infection? Study design Multi-center Double blinded RCT Population Characteristics of study participants 36.0% female N = 787 64.0% male 787 patients (282 female, 505 male) Inclusion criteria: adult patients admitted to the hospital for the management of COVID-19 Key exclusion criteria: previous treatment with a renin-angiotensin system blockade; hyperkalemia or unrecorded serum potassium; low eGFR; or unrecorded kidney function Interventions N=393 ARB (predominantly oral telmisartan at a starting dose of 40 mg/day for 28 days) N=394 placebo (matching placebo for 28 days) Primary outcome World Health Organization Scale score at day 14 1.0 1 1 0.8 0.5 https://web.pathway.md/studies/recGmL4ZNMLc1p86G 1/2 6/28/23, 12:10 AM CLARITY Pathway 0.3 Borderline significant increase 0.0 Angiotensin receptor blocker Placebo Borderline significant increase in WHO Scale score at day 14 (1 vs. 1; OR 1.51, 95% CI 1.02 to 2.23) Secondary outcomes No significant difference in death at day 28 (2.5% vs. 1.5%; OR 1.74, 95% CI 0.62 to 5.25) No significant difference in respiratory failure (6.6% vs. 5.1%; HR 1.32, 95% CI 0.74 to 2.43) Safety outcomes No significant differences in hyperkalemia, hypotension, AKI. Conclusion In adult patients admitted to the hospital for the management of COVID-19, ARB was not superior to placebo with respect to WHO Scale score at day 14. Reference Meg J Jardine, Sradha S Kotwal, Abhinav Bassi et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ. 2022 Nov 16;379:e072175. Open reference URL https://web.pathway.md/studies/recGmL4ZNMLc1p86G 2/2